Curaleaf split takes effect in New York trading as uplisting aims stall
Curaleaf’s 1-for-3 reverse stock split took effect Friday, raising its TSX share price to C$15.88 by mid-morning as the company aims to meet U.S. exchange listing criteria, just as rival Trulieve won NYSE approval; Curaleaf’s move comes amid sector gains and follows improved Q1 earnings, but no U.S. listing approval has been announced.